Welcome

You are Invited to a Virtual Webinar Program on the NOW APPROVED Joenja^® (leniolisib): The first and only approved treatment for Activated PI3Kδ Syndrome (APDS)

Please see below for Important Safety Information and full Prescribing Information

Please select from either of the presentations below to register for this event

speaker_headshot

Nicholas Hartog, MD
Physician and Clinical Assistant Professor
Helen DeVos Children’s Hospital
Spectrum Health Medical Group
Grand Rapids, Michigan

Tuesday, April 13, 2023 at 7:00 PM ET/4:00 PM PT

Register

speaker_headshot

Amit R. Mehta, MD
Hematologist, Oncologist
Premier Hematology & Tele-Oncology Center, PLLC
Cary, North Carolina

Thursday, May 4, 2023 at 7:00 PM ET/4:00 PM PT

Register

JOE-US-2023-0042v2 ©2023 Pharming, Inc. All rights reserved. Joenja and logo are registered trademarks of Pharming Intellectual Property, B.V.
For US audiences only.

INDICATIONS AND USAGE
JOENJA^® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

IMPORTANT SAFETY INFORMATION
Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA. JOENJA may cause fetal harm when administered to a pregnant woman.

Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA , please read the full Prescribing Information